Certara, Inc. (NASDAQ:CERT) Receives Consensus Rating of "Hold" from Brokerages

Certara, Inc. (NASDAQ:CERT - Get Free Report) has been given an average recommendation of "Hold" by the eight ratings firms that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $15.92.

Several analysts have weighed in on the stock. Robert W. Baird dropped their price objective on shares of Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, November 5th. UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a research report on Friday, September 27th. Finally, Barclays lowered their price objective on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th.

Certara Stock Performance

CERT stock traded up $0.05 during mid-day trading on Friday, hitting $13.26. 1,658,520 shares of the company were exchanged, compared to its average volume of 870,371. Certara has a 1-year low of $9.41 and a 1-year high of $19.87. The business has a 50 day simple moving average of $11.13 and a 200-day simple moving average of $11.88. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $2.13 billion, a PE ratio of -66.30, a price-to-earnings-growth ratio of 9.77 and a beta of 1.52.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analysts' expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period last year, the firm posted $0.06 EPS. On average, equities analysts forecast that Certara will post 0.28 earnings per share for the current year.

Hedge Funds Weigh In On Certara

Hedge funds and other institutional investors have recently modified their holdings of the business. Blue Trust Inc. raised its stake in Certara by 112.3% during the third quarter. Blue Trust Inc. now owns 3,925 shares of the company's stock worth $46,000 after acquiring an additional 2,076 shares in the last quarter. KBC Group NV boosted its holdings in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after acquiring an additional 1,584 shares in the last quarter. GAMMA Investing LLC grew its position in Certara by 442.2% during the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company's stock worth $90,000 after acquiring an additional 6,868 shares during the last quarter. Intech Investment Management LLC acquired a new position in Certara in the 2nd quarter worth about $152,000. Finally, Algert Global LLC bought a new position in Certara in the 2nd quarter valued at approximately $156,000. Institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.